Expression of NALP3 in the spleen of mice with portal hypertension.
This study examined the mRNA expression of NALP3 in the spleen of the mice with hypersplenism due to portal hypertension (PH). The mouse hypersplenism models were established by oral administration of tetrachloromethane (2 mL/kg/week for 12 weeks by oral gavage). All the mice were randomly divided into a control group and an experimental group. The blood routine test was conducted, spleen index was calculated and spleen was histologically examined. Portal vein sera were taken for detection of the level of uric acid. The mRNA expressions of NALP3 and IL-1beta in the spleen were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed that the platelet count was significantly lower in the experimental group [(674 + or - 102) x 10(9)/L] than in the control group [(1307 + or - 181) x 10(9)/L] (P<0.05), while the spleen index was significantly higher [(9.83 + or - 1.36) microg/g] in the experimental group than in the control group [(4.11 + or - 0.47) microg/g] (P<0.05). The histopathological changes of spleen followed the pattern of congestive splenomegaly. No significant difference was found in the uric acid level in the portal vein between the control group and the experiment group. The mRNA expressions of NALP3 and IL-1beta were up-regulated significantly in the spleen in the experimental group as compared with those in the control group (P<0.05). It was concluded that NALP3 and IL-1beta may play important roles in the pathogenesis of hypersplenism.
Xia
Zefeng
Z
Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. xiazefeng@sina.com
Wang
Guobin
G
Wan
Chidan
C
Liu
Tao
T
Wang
Shuai
S
Wang
Bo
B
Cheng
Rui
R
D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D006971:Hypersplenism / Q000209:etiology / Q000378:metabolism*; D006975:Hypertension, Portal / Q000150:complications / Q000378:metabolism*; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013154:Spleen / Q000378:metabolism*; D015854:Up-Regulation
D002352:Carrier Proteins; D053583:Interleukin-1beta; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C492716:Nlrp3 protein, mouse; D012333:RNA, Messenger
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):317-23
11338057
Nature. 2006 Jul 6;442(7098):39-44
16823444
Nature. 2006 Mar 9;440(7081):237-41
16407889
Immunol Cell Biol. 2010 Jan;88(1):20-3
19935768
Nat Rev Mol Cell Biol. 2003 Feb;4(2):95-104
12563287
Nat Clin Pract Rheumatol. 2008 Jan;4(1):34-42
18172447
Trends Cell Biol. 2009 Sep;19(9):455-64
19716304
Immunol Rev. 2009 Jan;227(1):95-105
19120479
Semin Immunopathol. 2007 Sep;29(3):213-29
17703304
Lipids Health Dis. 2008 Feb 13;7:4
18271959
Cytokine. 2005 Aug 7;31(3):213-26
15950486
J Matern Fetal Neonatal Med. 2008 Sep;21(9):605-16
18828051
Nature. 2008 Jul 24;454(7203):428-35
18650913
Nat Immunol. 2008 Aug;9(8):857-65
18604209
Baillieres Best Pract Res Clin Gastroenterol. 2000 Dec;14(6):1009-31
11139352
Immunity. 2004 Mar;20(3):319-25
15030775
Cell Death Differ. 2007 Jan;14(1):10-22
16977329
Nat Rev Immunol. 2005 Aug;5(8):606-16
16056254
Pathobiology. 1999;67(5-6):236-40
10725792
Br J Pharmacol. 2009 Aug;157(8):1318-29
19681864
Cell. 2006 Aug 25;126(4):659-62
16923387
Clin Lab Haematol. 2001 Apr;23(2):111-7
11488850
Mediators Inflamm. 2005 Jun 9;2005(2):101-11
16030393